M&A vibes amid earn­ings sea­son; CAR-T be­yond can­cer; Lil­ly dou­bles down on obe­si­ty; Two con­se­quen­tial FDA ap­provals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

What a week — it hon­est­ly felt more like a month. I can al­most guar­an­tee that you will read some­thing in this is­sue that you over­looked the past few days. As al­ways, we wel­come your feed­back on the for­mat and con­tent of the re­port. Just shoot me an email.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.